Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GRIP-IT PILOT: Volagidemab for Alpelisib-Induced Hyperglycemia
NCT04330625Phase 1Terminated
- Sponsor
- Duke University
- Start
- Nov 2020
- Primary completion
- May 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of volagidemab in hyperglycemia, sponsored by Duke University. Primary endpoints: Adverse Events at 28 days and Serious Adverse Events at 28 days. Started Nov 2020; status: terminated.
02
Drugs
volagidemab
03
Conditions
hyperglycemia
Beyond the preview
Go deeper on NCT04330625.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04330625.